Trial Profile
An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain; Pain
- Focus Adverse reactions
- Sponsors Mallinckrodt Inc.
- 01 Oct 2019 Status changed from recruiting to discontinued.
- 02 Jun 2017 Planned End Date changed from 1 Oct 2016 to 1 Jan 2019.
- 02 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2019.